Recombinant human PLAU / uPA Protein, His tag, 50µg

Background
Urokinase - type plasminogen activator is also known as PLAU and UPA, a serine protease with an extremely limited substrate specificity, cleaving the sequence Cys – Pro – Gly - Arg560 - Val561 – Val – Gly – Gly – Cys in plasminogen to form plasmin. uPA is a potent marker of invasion and metastasis in a variety of human cancers associated with breast, stomach, colon, bladder, ovary, brain and endometrium.uPA and its receptor (uPAR) have been implicated in a broad spectrum of pathophysiological processes, including fibrinolysis, proteolysis, inflammation, atherogenesis and plaque destabilization, all of which are involved in the pathogenesis of MI (myocardial infarction).

Source
Recombinant human PLAU / uPA Protein, His Tag (PLU-H5229) is expressed from human 293 cells (HEK293). It contains AA Ser 21 - Leu 431 (Accession # NP_002649.1).
Predicted N-terminus: Ser 21

Molecular Characterization
Human PLAU, His Tag is fused with a polyhistidine tag at the C-terminus, and has a calculated MW of 47.2 kDa. The protein migrates as 45-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Please note that the protein is not activated by protease digestion. In vitro activation is generally recommended for higher activity.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>92% as determined by SDS-PAGE.

Bioactivity
Please refer to product data sheet.

Formulation
Lyophilized from 0.22 μm filtered solution in 50 mM Sodium Acetate, 100 mM NaCl, pH5.0 with trehalose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Proteomic analysis of exosomes secreted during the epithelial-mesenchymal transition and potential biomarkers of mesenchymal high-grade serous ovarian carcinoma"
Ferreira, Thomé, Izumi et al
J Ovarian Res (2023) 16 (1), 232
(2) "Head and neck squamous cell carcinoma-specific prognostic signature and drug sensitive subtypes based on programmed cell death-related genes"
Xu, Xu, Liu
PeerJ (2023) 11, e16364
(3) "IEffects of copy number variations on longevity in late-onset Alzheimer's disease patients: insights from a causality network analysis"
Hao, Li, Wang et al
Front Aging Neurosci (2023) 15, 1241412
Showing 1-3 of 582 papers.